Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1087319 | 0.87 | USP2 (0.51) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL27341005 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL1088665 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL6503080 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL10201515 | 0.85 | CYP2D6 (0.47) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL8242595 | 0.85 | USP2 (0.61) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL9379952 | 0.84 | USP2 (0.49) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 | |
| SCHEMBL18294 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2ALDH1A1 | |
| SCHEMBL698803 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDEPHX2ALDH1A1 | |
| SCHEMBL863104 | 0.83 | USP2 (0.55) | USP2SMN1; SMN2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9993554-B2 | Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2018-06-12 | — | — | US | disclosed |
| US-9745321-B2 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9745321-B2 | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2017-08-29 | — | — | US | disclosed |
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9499561-B2 | Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2016-07-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | SHANGHAI YUNYI HEALTHCARE AND TECHNOLOGY CO., LTD. (CN) | 2015-09-03 | — | — | US | disclosed |
| US-8778935-B2 | Imidazopyrazines for use as kinase inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-07-15 | — | — | US | disclosed |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-06-05 | — | — | US | disclosed |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-05 | — | — | US | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214994-A1 | FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF | PIK3CA, WEE1, TKFC | USP2 4643/4885SMN1; SMN2 4341/4885CHRM2 4348/4885 |
| US-20140154232-A1 | Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing | PLIN1, PCK2, PLIN3 | USP2 1248/4885SMN1; SMN2 4588/4885CHRM2 4411/4885 |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | USP2 2606/4885SMN1; SMN2 2884/4885CHRM2 1973/4885 |
| US-20120083492-A1 | IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | USP2 3475/4885SMN1; SMN2 3221/4885CHRM2 3020/4885 |
| US-20150246929-A1 | FUSED PYRIMIDINE COMPOUND, AND PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | USP2 4088/4885SMN1; SMN2 2866/4885CHRM2 4441/4885 |
| US-20160024080-A1 | NEW COMPOUNDS | QSOX1, MAOB, MAOA | USP2 4411/4885SMN1; SMN2 720/4885CHRM2 2036/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | USP2 1390/4885SMN1; SMN2 3410/4885CHRM2 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.